Weekly Spotlight - 27.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

South Korea Approves Nefecon for Primary IgA Nephropathy Treatment

South Korea has approved Nefecon, a drug developed by Everest Medicines, for the treatment of primary iga nephropathy. This approval marks a significant advancement in managing the condition, offering a new therapeutic option to patients suffering from iga nephropathy. The drug aims to reduce proteinuria and slow disease progression.

New Gene Therapy Targets Kidney Cells in Rare Disease Treatment

Researchers are developing a new gene therapy, PS-002, to target podocytes in the kidneys of people with iga nephropathy. This therapy aims to protect these crucial cells and potentially slow or halt the progression of the disease. Early trials show promising results in improving kidney function.

Link Between Inflammatory Skin Conditions and Kidney Disease Identified in New Study

Research suggests a link between inflammatory skin diseases, such as psoriasis and atopic dermatitis, and an increased risk of developing iga nephropathy. The study highlights that patients with these skin conditions may need closer monitoring for kidney health. This connection could help in early detection and management of iga nephropathy.

How IgA Nephropathy Affects Patients' Quality of Life and Well-being

Living with iga nephropathy can significantly impact quality of life, affecting physical health, mental well-being, and social interactions. Symptoms like fatigue, pain, and frequent hospital visits can limit daily activities and emotional stability, highlighting the need for comprehensive care and support to manage the condition effectively.